Foghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Our proprietary Gene Traffic Control® platform gives us an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing us to identify, validate and potentially drug targets within the system.

Flagship Pioneering

Casdin Capital

Invus

Irving Investors

Foghorn Therapeutics Inc.

Happy New Year from all of us at Foghorn! As we kick off 2024, we look forward to the year ahead as we continue to advance our mission to transform patient’s lives by correcting abnormal gene expression. #biotechnology #innovation #oncology

Check out photos of our Foghorn team, who had fun swapping surprises at our end of year holiday party. From all of us at Foghorn, wishing everyone a healthy and happy holiday season! #HappyHolidays

That's a wrap on the 65th Annual American Society of Hematology Meeting! Our team enjoyed coming together with the scientific community to present data and talk about our novel approach to modulating the chromatin regulatory system. Read all of our recent data presentations from #ASH23 and beyond: https://bit.ly/3GJ2vkZ

Martin (Murphy) Hentemann Kathleen Healy Caroline Almon #biotechnology #innovation #TPD

Meet Alexia Kalogeropulou, one of our brilliant scientists at Foghorn. Alexia shares why she loves the collaborative culture that enables us to advance our mission to transform the lives of people living with a wide spectrum of diseases. #LifeAtFoghorn #WomenInSTEM #biotechnology

Join us at the 2nd Annual TPD Assay Development & Screening Summit, where our Head of #DrugDiscovery, Marina Nelen, will be part of a panel to discuss high-throughput screening approaches and applications of assay techniques to degrader triage and profiling. See the agenda: https://ow.ly/J9Bh50QfwVc
#biotechnology #innovation #proteindegradation

We’re looking forward to the 65th American Society of Hematology Annual Meeting and Exposition, where clinical data from the Phase 1 dose-escalation study of FHD-286 in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) will be presented. Learn more: https://ow.ly/wc3q50Qel4h
#ASH23

We know that our people are the key to our success, which is why we embrace a people first culture. Our culture is just one reason that Madeleine Henley was drawn to Foghorn. Learn more about our culture: https://ow.ly/Ca4050Qe2u8 

#LifeAtFoghorn #WomenInSTEM

Happy #Thanksgiving to all! Today, we are especially thankful for the incredible Foghorn team and their unwavering commitment to our mission of transforming lives across a wide spectrum of diseases. #biotechnology #innovation

Last week, we had the pleasure of joining other leading experts in the chromatin and epigenetics field during #Epi2023, where Dave Lahr gave a presentation on our preclinical work during a session on the nucleosome and chromatin remodeling. Find all our recent data presentations here: https://lnkd.in/gUtu9Wfi

#biotechnology #oncology #innovation

Congratulations to this year's recipients of the 2023 Paul Marks Prize for Cancer Research, including our scientific co-founder, Cigall Kadoch! This award underscores the important work being done at Foghorn to address breakdowns in the chromatin regulatory targets to advance novel treatments in cancer and beyond. #oncology #cancerresearch #innovation

Viewport Meta

IPhone / Mobile Compatible

Euro

Google Tag Manager

Apple Mobile Web Clips Icon

HSTS

Google Font API

DNSSEC

Google Maps

WordPress

President & CEO

Adrian Gottschalk

Chief Financial Officer

Allan Reine

Chief Legal Officer

Michael J. LaCascia

Legal

Andrew Germain

Vice President of Investor Relations and Corporate Communications

Ben Strain

Chief People Officer

Carlos Mateu

Vice President, Head of IT

Dan Dinu

Vice President, Protein Degradation Platform

Danette Daniels

SVP, Head of Business & Operations

Fanny Cavalie

Vice President Regulatory Affairs

Jackie Cinicola

Michael Mendelsohn

Igor Sill

Seed Investor

Carl Decicco

Chief Scientific Officer

Carl P. Decicco

Steven Bellon

Cigall Kadoch

Scientific Founder

Alfonso Quintás-Cardama

Anna Rivkin

Northeastern US Companies With Less Than $50M in Revenue (Top 10K)

East Coast Public Companies With Less Than $1B in Revenue

Greater Boston Area Biotechnology Companies

Biopharma Companies

Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order.By manipulating this system with our unique Gene Traffic ControlTM platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us—and rewrite destiny for millions of people living with disease.With Gene Traffic ControlTM Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.

Post-IPO Equity - Foghorn Therapeutics

Venture Round - Foghorn Therapeutics

Cambridge

Massachusetts

United States

North America

Foghorn Therapeutics

North American Morning Briefing : Stock Futures -2-

Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update

Foghorn Therapeutics announces first patient dosed with FHD-909

Foghorn Therapeutics to Participate in the BMO Oncology Summit

Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer

Wall Street Analysts Think Foghorn Therapeutics Could Surge 81.16%: Read This Before Placing a Bet

Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline

Foghorn Therapeutics Q1 2024 Earnings: Misses Analyst Revenue Projections Amidst Strategic ...

Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update

Flagship Pioneering funds acquire over $20 million in Foghorn Therapeutics warrants By Investing.com

A proprietary platform used for discovering and developing therapies by targeting the chromatin regulatory system.

An enzymatic inhibitor targeting BRG1 and BRM for treating acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

Targets cancers with mutations in the BRG1 subunit of the BAF complex.

Targets cancers with mutations in the ARID1A subunit of the BAF complex.

United Kingdom

Europe

France

Pakistan

Asia

Vedanta Biosciences is a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally defined consortia of human microbiome-derived bacteria.

Vedanta Biosciences Inc

Visterra is a biotechnology company that develops novel antibody-based therapies for the treatment of infectious diseases.

Visterra Inc

Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company that focuses on discovering and developing medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

news impact assignment basic	general	Feb 8, 2024 2:19 PM	2d73bcb1
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Feb 8, 2024 2:19 PM	e9611f3f
company summary	general
signals	general
crunchbase trigger	general	Nov 25, 2024 9:06 AM	4327691a
crunchbase profile	general	Nov 25, 2024 11:37 AM	856c65cc
li profile	general	Feb 8, 2024 2:19 PM	fa9220cf
translate crunchbase fundingrounds	general	Nov 25, 2024 2:13 PM	3effb096
peers	general	Feb 8, 2024 2:19 PM	20146dd7
news basic	general	Feb 8, 2024 2:19 PM	41293ed5
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:FOGHORNTX

Foghorn Therapeutics Inc.

Last Close

7.72

22/11 21:00

Market Cap

265.58M

Beta: -

Volume Today

100.07K

Avg: -